Core Viewpoint - In a slowing global beauty industry, Galderma, a skin-focused company, has achieved significant growth, with net sales surpassing $5 billion for the first time, reaching $5.207 billion (approximately 358.92 billion RMB), a year-on-year increase of 17.7% [3][4]. Financial Performance - Galderma's record financial performance in 2025 includes growth across all product categories and major regional markets, driven by a clear strategic positioning and a science-based innovation approach [4]. - The company projects a net sales growth of 17%-20% for 2026 at constant exchange rates, with core EBITDA margin expected to reach approximately 26% [4]. Market Position - Galderma ranks 11th among global beauty groups with a revenue of $5.207 billion, closing the gap with the 10th place Coty, which is only about $500 million ahead [7]. - The company's growth is attributed to the success of its three main business segments, which complement each other in revenue contribution, profit margins, innovation potential, and resilience [7]. Business Segments - The Injectable Aesthetics segment is the largest revenue source, with net sales of $2.572 billion, showing a year-on-year growth of 11.5% [8]. - The Dermatological Skincare segment generated net sales of $1.449 billion, with a year-on-year increase of 9.3%, driven by strong performances from brands like Cetaphil and Alastin [8]. - The Therapeutic Dermatology segment experienced the fastest growth, with net sales of $1.185 billion, a remarkable year-on-year increase of 50.2%, largely due to the performance of the Nemluvio brand [8]. Strategic Execution in China - China has become a key testing ground for Galderma's strategic execution, with a focus on integrating global products, cross-segment collaboration, and local research to build a comprehensive health management system [9]. - The brand Cetaphil has been a significant driver of growth in China, particularly during promotional events like Double Eleven, outperforming the overall skincare market [9]. Product Innovations - In 2025, Galderma introduced several key products to the Chinese market, including the globally recognized regenerative aesthetic product Sculptra, marking a strategic move into the Chinese regenerative aesthetic market [11]. - The launch of the innovative perioperative skincare brand Alastin further extends the company's offerings from treatment to pre- and post-procedure care, creating a complete "injection + care" loop [11]. Research and Development - Galderma is advancing its R&D investments in China, with a clinical study focusing on the biological impacts of lifestyle and environmental factors on sensitive skin populations [13]. - The company has established a robust R&D network with over 650 personnel across 33 global research bases, emphasizing clinical validation and efficacy in product development [20]. Competitive Landscape - The global beauty industry is witnessing a shift towards medical aesthetics, with major players like L'Oréal and Estée Lauder increasing their focus on this high-growth segment [14][15]. - Galderma's unique vertical integration model allows it to meet diverse consumer needs across different skin conditions and life stages, creating a competitive moat that traditional beauty brands find hard to replicate [21].

Group 1 - The core point of the article is that Estée Lauder Companies reported a strong performance in Q2 of fiscal year 2026, with net sales increasing by 6% year-over-year and net profit turning from a loss of $590 million in the same period last year to a profit of $162 million [1] - The company highlighted that the sales in the mainland China market showed robust performance with double-digit organic growth for two consecutive quarters, becoming a key driver of the company's performance recovery [1] - Estée Lauder's Q2 net sales reached $4.2 billion, with an adjusted operating margin improving from 11.5% to 14.4%. The company raised its full-year organic sales growth forecast to 1% to 3% and anticipates the first expansion in operating margin in four years [1] Group 2 - The CEO of Estée Lauder, Fabrizio Freda, stated that the second-quarter performance was exceptional, further solidifying the strong momentum for the first half of fiscal year 2026. The "Reinventing Beauty" strategy has injected new vitality into the business, driving the largest operational, leadership, and cultural transformation in the company's history [2] - Estée Lauder, founded in 1946, owns several well-known brands including Estée Lauder, La Mer, Clinique, and M.A.C, and its business is categorized into five segments: skincare, makeup, fragrance, hair care, and others [2]

Core Points - Estée Lauder has completed the formation of a new executive team and announced its compensation plan for the fiscal year 2025, which includes base salary, pension, stock options, bonuses, and other benefits [1][2] - The overall annual target compensation for Estée Lauder's management has decreased by 28% following an internal restructuring [1][2] - The former CEO Fabrizio Freda's compensation has seen a significant reduction of 73%, while the current CEO's salary has dropped by approximately 50% compared to the previous CEO [1][3] Compensation Details - Fabrizio Freda, the highest-paid executive, will receive a total compensation of $17.8 million (approximately 127 million RMB) for the fiscal year 2025, with a portion consisting of stock options that may not realize full value due to stock price fluctuations [3][25] - Other executives have also experienced salary reductions, with the current CEO Stéphane de La Faverie earning $9.6 million (approximately 6.8 million RMB), a decrease of 46% from Freda's previous salary [26] - The current CFO Akhil Shrivastava's salary is $3.6 million (approximately 2.6 million RMB), reflecting a 52% drop from his predecessor [26] Performance Context - Estée Lauder has faced significant performance challenges, with net profits declining by 16%, 58%, and 60% from fiscal years 2022 to 2024, leading to a projected loss of $1.133 billion (approximately 808.5 million RMB) for fiscal year 2025 [28][30] - The company's sales and net profits have decreased, with Q4 of fiscal year 2025 reporting sales of $3.411 billion (approximately 24.34 billion RMB), a 12% year-over-year decline [30] Strategic Response - In response to ongoing performance issues, Estée Lauder has initiated significant reforms, including the establishment of a new leadership team and the launch of the "Beauty Reimagined" brand revitalization plan [33][34] - The return of veteran executive Lisa Sequino aims to strengthen the strategic planning and global growth of key makeup brands within the company [35] - The management's collective salary reductions highlight the direct correlation between the company's performance challenges and stock price volatility, emphasizing the need for strategic adjustments to restore market confidence and achieve long-term growth [38]

Core Viewpoint - Estée Lauder is facing significant challenges in its recovery path, with a decline in net sales and operating income amid economic downturns and geopolitical factors [1][3]. Financial Performance - For the fiscal year 2025, Estée Lauder reported a net sales decline of 8% year-over-year, totaling $14.33 billion (approximately ¥1028.01 billion) [1][2]. - The company's gross profit decreased by 5% to $10.60 billion, with a gross margin of 74.0% [2]. - Operating income turned into a loss of $785 million, marking a significant decline from a profit of $970 million in the previous year [2][6]. - The diluted net loss per share was $3.15, compared to earnings of $1.08 per share in the prior year [2]. Business Segment Performance - The only category to show growth was the fragrance segment, which remained flat with a slight increase, while skincare, makeup, and hair care categories experienced declines of 12%, 6%, and 10% respectively [4][6]. - The skincare segment's decline was attributed to decreased sales of brands like Estée Lauder and La Mer, alongside a drop in Asian travel retail sales [7][11]. - The makeup segment's downturn was primarily due to poor performance from brands like M·A·C and Too Faced [7][8]. Regional Performance - All regions reported declines in net sales, with the EMEA region experiencing the largest drop of 12%, followed by Asia/Pacific at 7% and the Americas at 4% [10][11]. - In mainland China, net sales fell by 6%, influenced by a challenging retail environment and low consumer sentiment [11][14]. Strategic Initiatives - Estée Lauder is undergoing a restructuring plan (PRGP) aimed at restoring profitability, which has already led to over 3,200 job cuts, with projections of total cuts reaching between 5,800 to 7,000 positions [19][22]. - The company anticipates that the restructuring will incur pre-tax costs between $1.6 billion to $3.3 billion [19]. Future Outlook - Despite current challenges, Estée Lauder's management expressed confidence in achieving organic sales growth in fiscal year 2026 and aims to rebuild operational profitability [3][22]. - The company plans to report its financials based on a new geographical structure starting Q1 of fiscal year 2026, which will include China as a separate reporting region [11][19].